PolarityTE tumbles as FDA puts skin repair product on clinical hold

RegenETP,

24/08/2021 14:54

** Shares of regenerative tissue developer PolarityTE Inc
 PTE.O  slide 23.4% to 64 cents, their lowest in 8 months
    ** PTE says FDA has put its application for testing SkinTE
in chronic cutaneous ulcers on clinical hold  urn:newsml:reuters.com:*:nBw8dCLYsa
    ** SkinTE is the company's FDA-registered, commercially
available product for people who require skin regeneration
treatment, such as after wounds and burns
    ** PTE says FDA gave it feedback saying certain chemistry,
manufacturing, and control (CMC) items need to be addressed
first before it can begin trials
    ** Up to Monday's close, stock had risen 23.1% YTD

 (Reporting by Ruhi Soni in Bengaluru)
 ((Ruhi.Soni@thomsonreuters.com;))